Skip to main content

ENDO: Teprotumumab Shows Long-Term Efficacy for Thyroid Eye Disease

Medically reviewed by Carmen Pope, BPharm. Last updated on June 11, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, June 11, 2024 -- Most patients with thyroid eye disease treated with teprotumumab do not require additional treatments nearly two years later, according to a study presented at the annual meeting of the Endocrine Society, held from June 1 to 4 in Boston, and simultaneously published online June 2 in Thyroid.

George J. Kahaly, M.D., Ph.D., from the Johannes Gutenberg University Medical Center in Mainz, Germany, and colleagues analyzed the long-term maintenance of responses with teprotumumab from previous trials. The analysis included 112 patients who received seven or eight infusions of teprotumumab in the phase 2, phase 3 (OPTIC study), and OPTIC Extension (OPTIC-X) studies.

The researchers found that at week 72, 52 of 57 patients were responders for clinical activity score (CAS ≥2-point improvement), 51 of 57 were responders for the European Group of Graves' Orbitopathy ophthalmic composite outcome, 35 of 48 were responders for diplopia (≥1 Gorman grade improvement), 38 of 56 were responders for proptosis (≥2-mm improvement), and 37 of 56 had an overall response (improvement in proptosis plus CAS). The mean reduction in proptosis was 2.68 mm, while disease inactivation (CAS ≤1) was detected in 40 of 57 participants. Mean Graves' Ophthalmopathy quality-of-life score improvement was 15.22. At 99 weeks, 17.9 percent of patients reported additional thyroid eye disease therapy during formal and extended follow-up.

"As physicians consider treatment approaches for their thyroid eye disease patients, they now have longer-term data to support the use of teprotumumab in appropriate patients," Kahaly said in a statement.

The study was sponsored by Amgen, the manufacturer of teprotumumab.

Abstract/Full Text

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted June 2024

Read this next

Potential Genetic Link ID'd Between Thyroid Disease, Alopecia Areata

WEDNESDAY, Oct. 30, 2024 -- There seems to be a significant association between hypothyroidism, Hashimoto thyroiditis, subacute thyroiditis, and alopecia areata (AA), according to...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.